Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Otsuka Signs Contract with Celera Genomics for Genomic Database
December 3, 2001
- OTC NEWS IN BRIEF
December 3, 2001
- Kyorin Beefs Up Globalization by Forming Subsidiary in Europe
December 3, 2001
- Semi-annual Sales of OTC Drugs Up 1.1% from Last Year: INTAGE Survey
December 3, 2001
- REGULATORY NEWS IN BRIEF
December 3, 2001
- Current Price Gap Estimated to Be About 8%
December 3, 2001
- Decreases in Medical Fees Not Proposed by Gov't WT
December 3, 2001
- Ono to Start Overseas Business in Earnest: President Matsumoto
December 3, 2001
- Chuikyo Hearing: Industry Insists on Market Price Principle
December 3, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 3, 2001
- 5 New Drugs Including Synagis, Leustatin Recommended for Approval
December 3, 2001
- BUSINESS NEWS IN BRIEF
November 26, 2001
- Remicade, Simulect Designated as Orphans
November 26, 2001
- Pressure on Medical Fees Gains Momentum
November 26, 2001
- LDP Summarizes Its Proposals for Healthcare Reform
November 26, 2001
- Post-marketing Safety Is Int'l Issue: Dr Doi
November 26, 2001
- Marketing Approval Is Being Considered by Korosho : Seminar
November 26, 2001
- REGULATORY NEWS IN BRIEF
November 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 26, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 26, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…